Featured Research

from universities, journals, and other organizations

Saving the heart in breast cancer treatment

Date:
July 17, 2014
Source:
ecancer
Summary:
Breast cancer awareness campaigns stress saving the breasts - but what about the heart? Breast cancer patients who are positive for the HER2 gene may be at increased risk for heart damage during chemotherapy, according to a new study. Cardio-oncology is a relatively new field of research, emerging as scientists and doctors understand the connections between cancer treatment and the heart.

Breast cancer awareness campaigns stress saving the breasts -- but what about the heart?

Breast cancer patients who are positive for the HER2 gene may be at increased risk for heart damage during chemotherapy, according to a new study published in ecancermedicalscience.

Patients with the HER2 gene are often treated with trastuzumab or lapatinib, which interfere with its cancer-causing signals.

However, researchers at the University of Louisville, Kentucky and Kentucky One Health noted that some patients' hearts seemed to be weakening under treatment.

"Breast cancer patients treated with either trastuzumab or lapatanib may have an increase in stress hormones (catecholamines), a decrease in protective growth factor (neuregulin), and an increase in blood pressure," says lead author Dr Carrie Geisberg Lenneman. "This may contribute to why certain patients have a decline in heart function during chemotherapy treatment."

Cardio-oncology is a relatively new field of research, emerging as scientists and doctors understand the connections between cancer treatment and the heart.

"We hope that physicians will consider treating hypertension that may arise in breast cancer patients," Dr Lenneman says, suggesting that existing treatments such as beta-blockers may mitigate the damage.

"Hopefully, this study will lead to larger clinical trials examining the role of beta-blockers as cardioprotective therapy in the HER2-positive treated patients."


Story Source:

The above story is based on materials provided by ecancer. Note: Materials may be edited for content and length.


Journal Reference:

  1. Carrie G Lenneman, Wissam M Abdallah, Holly M Smith, Vandana Abramson, Ingrid A Mayer, Cheri Silverstein, Julie Means-Powell, Sachin Y Paranjape, Daniel Lenihan, Douglas B Sawyer and Satish R Raj. Sympathetic nervous system alterations with HER2 antagonism: an early marker of cardiac dysfunction with breast cancer treatment? ecancermedicalscience, July 2014 DOI: 10.3332/ecancer.2014.446

Cite This Page:

ecancer. "Saving the heart in breast cancer treatment." ScienceDaily. ScienceDaily, 17 July 2014. <www.sciencedaily.com/releases/2014/07/140717094818.htm>.
ecancer. (2014, July 17). Saving the heart in breast cancer treatment. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2014/07/140717094818.htm
ecancer. "Saving the heart in breast cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2014/07/140717094818.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins